Standout Papers

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidan... 2015 2026 2018 2022 4.9k
  1. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2017)
    Naga Chalasani, Zobair M. Younossi et al. Hepatology
  2. Mechanisms of NAFLD development and therapeutic strategies (2018)
    Scott L. Friedman, Brent A. Neuschwander‐Tetri et al. Nature Medicine
  3. Nonalcoholic Fatty Liver Disease (2015)
    Mary E. Rinella JAMA
  4. Non-alcoholic fatty liver disease (2021)
    Elizabeth E. Powell, Vincent Wai‐Sun Wong et al. The Lancet
  5. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (2023)
    Mary E. Rinella, Brent A. Neuschwander‐Tetri et al. Hepatology
  6. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease (2020)
    Thomas G. Cotter, Mary E. Rinella Gastroenterology
  7. Nonalcoholic fatty liver disease (2015)
    Elizabeth M. Brunt, Vincent Wai‐Sun Wong et al. Nature Reviews Disease Primers
  8. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings (2022)
    Kenneth Cusi, Scott Isaacs et al. Endocrine Practice
  9. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (2018)
    Stephen A. Harrison, Mary E. Rinella et al. The Lancet
  10. From NAFLD to MAFLD: Implications of a Premature Change in Terminology (2020)
    Zobair M. Younossi, Mary E. Rinella et al. Hepatology
  11. Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature (2023)
    Jeffrey V. Lazarus, Philip N. Newsome et al. Hepatology
  12. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial (2021)
    Rohit Loomba, Rizwana Mohseni et al. Gastroenterology
  13. Metabolic dysfunction–associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease (2023)
    Fasiha Kanwal, Brent A. Neuschwander‐Tetri et al. Hepatology
  14. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease (2023)
    Mary E. Rinella, Silvia Sookoian Journal of Lipid Research
  15. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study (2024)
    Mads Israelsen, Nikolaj Torp et al. ˜The œLancet. Gastroenterology & hepatology
  16. Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis (2024)
    Mazen Noureddin, Michael Charlton et al. Clinical Gastroenterology and Hepatology
  17. Metabolic dysfunction-associated steatotic liver disease in adults (2025)
    Daniel Q. Huang, Vincent Wai‐Sun Wong et al. Nature Reviews Disease Primers
  18. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (2025)
    Mazen Noureddin, Mary E. Rinella et al. New England Journal of Medicine

Immediate Impact

11 from Science/Nature 198 standout
Sub-graph 1 of 13

Citing Papers

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide
2024 Standout
24 intermediate papers

Works of Mary E. Rinella being referenced

Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices
2020
Systematic review with meta‐analysis: risk of hepatocellular carcinoma in non‐alcoholic steatohepatitis without cirrhosis compared to other liver diseases
2018
and 17 more

Author Peers

Author Last Decade Papers Cites
Mary E. Rinella 17635 7139 7399 127 20.4k
Leon A. Adams 18336 8886 7643 198 22.2k
Quentin M. Anstee 18861 8645 7626 247 22.8k
Geoffrey C. Farrell 19440 9801 6780 213 25.5k
Melissa J. Contos 15606 7133 5864 58 18.1k
Mark L. Van Natta 14287 6182 5335 111 18.7k
Matthew M. Yeh 13136 5819 4449 127 16.7k
Joel E. Lavine 23582 9615 11524 144 27.6k
Paul Angulo 21596 11575 9010 155 25.9k
Michael Charlton 18908 12598 6056 247 24.5k
Brent A. Neuschwander‐Tetri 24212 9883 10995 186 29.7k

All Works

Loading papers...

Rankless by CCL
2026